Yang Chao-tang, Chairman of PET Pharm Biotech (G-SURE), announced that the company signed a technology transfer agreement this April with DuChemBio, South Korea's largest radiopharmaceutical firm. This partnership focuses on introducing advanced tracers to the Taiwan market...
G-SURE Biotech (7762-TW), the leading domestic radiopharmaceutical company, states that the demand for nuclear medicine is trending upward alongside population aging and precision medicine...
G-SURE Biotech Accelerates Expansion into the Radiopharmaceutical Blue Ocean; Acquires 80% Stake in Leman Biotech for NT$110 Million in March.
G-SURE Biotech (7762-TW) announced today (21st) the signing of a technology transfer agreement with South Korea's DuChemBio. The partnership focuses on the development, manufacturing, and commercialization of '18F-FP-CIT'...
G-SURE Biotech (7762-TW) enters into a technology transfer agreement with South Korea-based DuChemBio Co., Ltd. for the development, manufacturing, and commercialization of $^{18}Ftext{-FP-CIT}$, a PET radiopharmaceutical indicated for the diagnosis of Parkinson's Disease.
Terry Lin, General Manager of PPhB, stated that following the acquisition of the nuclear medicine startup Lemen BioScientific Co., Ltd. in 2025, the company has successfully integrated the Kaohsiung Luzhu plant into its production network.
PPhB (7762) continues to scale its operations. Following its acquisition of Lemen BioScientific, PPhB is investing over NT$1.5 billion in a new Nuclear Medicine Factory in Miaoli. Construction begins in Q2 2026, with production and certification targets set for late 2027.
Staging a powerful debut-day honeymoon rally, G-SURE led the pack, followed by Santis with a 16.62% gain in second place, and LongTime Tech securing third with a 10.54% increase.
G-SURE Biotech (7762-TW) debuted on the Emerging Stock Board today at a reference price of NT$28. The stock opened at NT$33.5 and surged to a high of NT$40.6, representing a remarkable intraday gain of 45%.